9^th July 2020 (7:45), Gosselies (Belgium) and Evry (France): OncoDNA SA and IntegraGen SA (Paris: ALINT) announce the signature on July 8th 2020 of an agreement under which the Belgian company OncoDNA will file today a friendly cash tender offer to purchase the shares of the French company IntegraGen, whose securities are admitted to trading on the Euronext Growth market of Euronext Paris, at a price per share of €2.20, valuing IntegraGen share capital at €14.5m1 for 100%.

June 17^th, 2020: Concordia Plan Services, a benefits provider for over 6,000 LCMS organizations worldwide, today announced that they will begin to offer their members access to SWORD Health's digital therapy programs for musculoskeletal pain.

June 15^th, 2020: SWORD Health, a digital musculoskeletal and pulmonary therapy provider, today announced the appointment of seven accomplished leaders to their executive team:

VENICE, California., May 27^th, 2020: DEARhealth Inc., a health tech company focused on AI-powered disease management, announced today the global launch of its DEARhealth platform in the Epic App Orchard online marketplace. Organizations using Epic, including health systems, hospitals, and clinics, can now access DEARhealth directly through the marketplace instead of traditional external integration, saving significant time, costs, and staff resources.

New York, February 27^th, 2020: SWORD Health (SWORD), a tech-enabled provider of musculoskeletal care, today announced the addition of $9 million to their Series A investment, bringing their total Series A investment to $17 million.

Munich, January 20th, 2020 – Prosthetic feet from the 3D printer are no longer an utopia, but reality. The combination of designing a foot in the computer and fast production through 3D printing creates a completely new ability to act, as Mercuris GmbH proves.

Gosselies, Belgium – February 14^th, 2020 – OncoDNA ("OncoDNA or "the Company"), the healthcare technology company making precision medicine a reality, today announced that it has completed a €19 million ($20 million) Series B equity financing.

Munich, Germany / February 10^th, 2020. – Successful Munich-based medical technology company Mecuris will be led by a new CEO, Peter Fröhlingsdorf (50), a renowned industry expert. Since the beginning of January this year, Fröhlingsdorf has been managing the business of the up-and-coming medtech scale-up. The main goal for this financial year is to lead the company from the start-up into the growth phase. The CEO's expertise and numerous years of industry know-how will be decisive in this process.

Munich, Germany, January 13^th, 2020 – German med-tech company Mecuris GmbH has successfully concluded a new funding round amounting to 3.6 million euros. In addition to the seed investors Bayern Kapital and High-Tech Gründerfonds (HTGF), the international investment company Mulcan, life science venture capital investor Vesalius Biocapital, and Sana Kliniken AG, one of the top five hospital chains in Germany, are once again also on board.

München, 13.12.2019 – Die Bundesregierung sieht großes Potenzial im Einsatz von 3D-Druck in der Medizintechnik – insbesondere für patientenindividuelle Sonderanfertigungen von Prothesen oder Orthesen. Das geht aus der Antwort auf die kleine Anfrage der FDP-Bundestagsfraktion „Prothesen aus dem 3D-Drucker für Menschen mit Behinderungen" hervor.